nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
Published 5 years ago • 7.3K plays • Length 37:23Download video MP4
Download video MP3
Similar videos
-
44:56
advanced nsclc: refining clinical pathways in the rapidly evolving therapeutic landscape
-
34:38
strategies for nsclc: clinical pathways in the era of biomarker-driven care
-
20:24
targeted treatment with egfr tkis: front line options
-
10:45
debate: adjuvant egfr-directed therapy for patients with early stage nsclc? - no
-
44:03
egfr: the challenge of primary and secondary resistance
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
20:35
tki-resistant egfr-mutant nsclc
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
26:13
therapeutic algorithm for nsclc adenocarcinoma
-
13:26
debate: drug of choice for exon 19 del egfr mutant nsclc - any egfr tki
-
16:22
debate: drug of choice for exon 19 del egfr mutant nsclc - afatinib
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
33:23
improving survival and managing costs in nsclc: the role of clinical care pathways
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
1:26
first line treatment of egfr mutation-positive nsclc
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?